Ivantis, Inc. Announces 1-Year Results for Novel Glaucoma Treatment
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
IRVINE, Calif.--(BUSINESS WIRE)--Ivantis Inc., developer of the novel Hydrus™ Microstent device designed to lower eye pressure for glaucoma patients, will present results from the HYDRUS II Study at the World Glaucoma Congress bi-annual meeting (Vancouver) today. These are the first-ever reported results from a randomized, controlled, multi-center trial in the MIGS (micro invasive glaucoma surgery) space featuring an evaluation of a microstent device versus a comparator group without the confounding effect of topical medication.
Help employers find you! Check out all the jobs and post your resume.
IRVINE, Calif.--(BUSINESS WIRE)--Ivantis Inc., developer of the novel Hydrus™ Microstent device designed to lower eye pressure for glaucoma patients, will present results from the HYDRUS II Study at the World Glaucoma Congress bi-annual meeting (Vancouver) today. These are the first-ever reported results from a randomized, controlled, multi-center trial in the MIGS (micro invasive glaucoma surgery) space featuring an evaluation of a microstent device versus a comparator group without the confounding effect of topical medication.
Help employers find you! Check out all the jobs and post your resume.